Table 1.
Study | Sample (M/F) | Age, mean | Country | Last visit (mo) | Intervention | Helicobacter pylori eradication |
Ang, 2006 | 130 (47/83) | 38.0 | Singapore | 12 | LAC | 73.2% |
Blum, 1998 | 328 (136/192) | 47.0 | Global | 12 | OAC | 79% |
Chiba, 2002 | 394 (148/246) | 49.5 | Canada | 12 | OMC | 75% |
Dhali, 1999 | 62 (44/18) | 32.5 | India | 12 | BMTe | 87.5% |
Froehlich, 2001 | 144 (64/80) | 44.6 | Switzerland | 12 | LAC | 75% |
Gisbert, 2004 | 50 (15/35) | 41.5 | Spain | 12 | OAC | 76% |
Greenberg, 1999 | 100 (31/69) | 46.5 | United States | 12 | OC | 70.5% |
Gwee, 2009 | 82 (38/44) | 40.4 | Singapore | 12 | OCT | 68.3% |
Hsu, 2001 | 161 (78/83) | 50.9 | China | 12 | LMTe | 78% |
Koelz, 2003 | 181 (74/107) | 47.5 | Switzerland | 6 | AO | 51.7% |
Koskenpato, 2001 | 151 (52/99) | 51.7 | Finland | 12 | AMO | 82% |
Lan, 2011 | 195 (89/106) | 47.4 | China | 3 | RAC | 85.7% |
Malfertheiner, 2003 | 800 (380/420) | 46.2 | Germany | 12 | LAC | 63.9% |
Mazzoleni, 2006 | 89 (20/69) | 41.3 | Brazil | 12 | LAC | 91.3% |
Mazzoleni, 2011 | 404 (86/318) | 46.0 | Brazil | 12 | OAC | 88.6% |
McColl, 1998 | 318 (155/163) | 42.1 | United Kingdom | 12 | AMO | 88% |
Miwa, 2000 | 85 (40/45) | 51.5 | Japan | 3 | OAC | 85.4% |
Naeeni, 2002 | 157 (47/110) | 32.5 | Iran | 9 | ABM | 52.6% |
Sodhi, 2013 | 519 (169/350) | 44.5 | India | 12 | OAC | 69.9% |
Talley, 1999 | 293 (133/160) | 46.4 | United States | 12 | LCA | 80% |
Talley, 1999 (ORCHID) | 275 (98/177) | 50.0 | Australia | 12 | OAC | 85% |
Varannes, 2001 | 253 (112/141) | 51.0 | France | 12 | RaAC | 69% |
Varasa, 2008 | 48 (21/27) | 37.0 | Spain | 12 | RA | 81.4% |
Xu, 2013 | 396 (135/261) | 40.0 | China | 12 | ACE | 76.36% |
Zanten, 2003 | 157 (72/81) | 48.0 | Canada | 12 | LCA | 82% |
M/F: Male/female; A: Amoxillin; B: Bismuth salt; C: Clarithromycin; E: Esoprazole; F: Furazolidone; L: Lansoprazole; M: Metronidizole; O: Omeprazole; R: Rabeprazole; Ra: Ranitidine; T: Tinidazole; Te: Tetracycline.